2-oxobenzoxazolin-6-ylsulfonic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 2-oxobenzoxazolin-6-ylsulfonic acid
• 英文别名: 2-oxo-2,3-dihydro-benzoxazole-6-sulfonic acid；2-Oxo-2,3-dihydro-benzoxazol-6-sulfonsaeure；2-Oxobenzoxazoline-6-sulfonic acid；2-oxo-3H-1,3-benzoxazole-6-sulfonic acid
• 化学式: C₇H₅NO₅S
• 分子量: 215.186
• InChiKey: SXSBVVOHCWKOJR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-oxobenzoxazolin-6-ylsulfonic acid 在 氯磺酸 作用下， 反应 1.0h， 生成 2-氧代-2,3-二氢苯并恶唑-6-磺酰氯
  参考文献：
  名称：

  Benzazoles. 4. Synthesis and chemical reactions of 6-chlorosulfonylbenzoxazolin-2-ones

  摘要：

  The corresponding 6-chlorosulfonyl derivatives were synthesized from benzoxazolin-2-one and its 3-methyl derivative by treatment with chlorosulfonic acid. By treatment of the compounds obtained with water and other nucleophilic reagents (aliphatic and heterocyclic amines) 2-oxobenzoxazoline-6-sulfonic acids and a series of their amides were obtained, while reduction with SnCl2 center dot 2H(2)O gave 6-mercaptobenzoxazolin-2-ones.

  DOI：

  10.1007/s10593-011-0724-1
• 作为产物：
  描述：

  2-苯并唑啉酮 在 硫酸 作用下， 生成 2-oxobenzoxazolin-6-ylsulfonic acid
  参考文献：
  名称：

  DE197496

  摘要：

  公开号：

文献信息

• NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE
  申请人：Hoffmann-La Roche Inc.

  公开号：US20150099734A1

  公开（公告）日：2015-04-09

  The invention provides novel compounds having the general formula (I) wherein R 1 , R 2 , Y and W are as described herein, compositions including the compounds and methods of using the compounds.

  这项发明提供了具有一般化学式（I）的新化合物，其中R1、R2、Y和W如本文所述，包括该化合物的组合物以及使用该化合物的方法。
• [EN] AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS<br/>[FR] COMPOSES AZACYCLIQUES EN TANT QUE MODULATEURS DE RECEPTEURS D'ACETYLCHOLINE
  申请人：LILLY CO ELI

  公开号：WO2003062224A1

  公开（公告）日：2003-07-31

  Compounds comprising an aza-cyclic portion and an aromatic portion linked via a sulphur atom are disclosed. The compounds disclosed are selective modulators of beta 4 subtype nicotinic acetylcholine receptors and are useful for the treatment of dysfunctions of the central and autonomic nervous systems.

  本发明揭示了一种由一个氮杂环部分和一个芳香部分通过硫原子连接的化合物。所揭示的化合物是选择性调节β4亚型尼古丁酰胆碱受体的调节剂，并可用于治疗中枢神经系统和自主神经系统的功能障碍。
• SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS
  申请人：Buschmann Helmut H.

  公开号：US20100184772A1

  公开（公告）日：2010-07-22

  The present invention relates to substituted pyrazoline compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.

  本发明涉及一般式(I)的取代吡唑啉化合物、其制备方法、包含这些化合物的药物以及它们用于制备用于治疗人类和动物的药物的用途。
• Pyrrolopyrazine kinase inhibitors
  申请人：Bamberg Joe Timothy

  公开号：US20100267666A1

  公开（公告）日：2010-10-21

  The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q 1 , R, and X are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及一种新型吡咯吡嗪衍生物的使用，其化学式为I，其中变量Q1、R和X的定义如下所述，该化合物抑制JAK和SYK，并且对于治疗自身免疫和炎症性疾病有用。
• HISTAMINE-3 RECEPTOR ANTAGONISTS
  申请人：Wager Travis T.

  公开号：US20090131433A1

  公开（公告）日：2009-05-21

  This invention is directed to a compound of the formula Ia or Ib, as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro-intestinal tract, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above.

  本发明涉及公式Ia或Ib的化合物，如本文所定义，或其药学上可接受的盐; 包含公式I化合物的制药组合物; 一种治疗通过拮抗组胺H3受体可以治疗的疾病或症状的方法，该方法包括向需要此类治疗的哺乳动物注射上述的公式I化合物; 以及一种治疗选择自抑郁症、情绪障碍、精神分裂症、焦虑症、阿尔茨海默病、注意力缺陷障碍（ADD）、注意力缺陷多动障碍（ADHD）、精神障碍、睡眠障碍、肥胖症、头晕、癫痫、晕动病、呼吸系统疾病、过敏、过敏引起的气道反应、过敏性鼻炎、鼻塞、过敏性充血、充血、低血压、心血管疾病、胃肠道疾病、胃肠道高低运动性和酸性分泌的方法，该方法包括向需要此类治疗的哺乳动物注射上述的公式I化合物。